

Index

- absence epilepsy (AE)
 fMRI of network alterations in, 142–6
 model system studies of, 11–12
 acquired epilepsy, 41
 action potentials, neuronal firing patterns of, 86–7, 89, 94
 cognitive dysfunction
 mechanisms from, 93–4
 epilepsy mechanisms from, 93
 GLM modelling of, 88–91
 multi-unit recordings, 88–94
 point process modelling of, 89
 seizure mechanisms from, 91–3
 single unit recordings, 88–94
 AD. *See* Alzheimer's disease
 adaptation, by complex adaptive systems, 1
 ADs. *See* afterdischarges
 AE. *See* absence epilepsy
 AEDs. *See* anti-epileptic drugs
 afterdischarges (ADs), 74–7
 Kuramoto model of, 75–8, 82–4
 spatial scales of, 77–9
 agents, of complex adaptive systems, 1
 aggregates, of complex adaptive systems, 1
 alpha rhythm, EEG, 72–4, 77–9
 Alzheimer's disease (AD), 10
 anti-epileptic drugs (AEDs). *See also* drug-resistant epilepsy
 complex systems theory understanding of, 3–4
 epilepsy genetic revolution and, 6
 fMRI-derived networks and, 146–7
 neuronal unit scale approaches to, 86, 93–4
 personalised network modelling and, 67–8
 response to, 28, 41–2, 61, 127, 146–7
 atrophy, personalised network modelling of, 65
 attractors, in dynamical system theory, 45–7
 autism spectrum disorder, 10
 awakening seizures, 51
 basal ganglia, in secondary generalised seizures, 138–40
 basis functions, for GLM modelling, 90–1
 behavioural comorbidities of epilepsy, 86, 94
 bifurcations, in phenomenological models of seizure activity, 45–50
 applications of, 53–7
 onset/offset mechanisms, 47–52
 seizure evolution, 52–3
 biomarkers
 of single-node epileptogenicity, 101–2, 115–16
 frequency-specific, 102–4
 multi-spectral, 103–5
 small RNA-seq in detection of, 29
 bistability, in dynamical system models of seizure, 45–8
 bistable models, of noise-induced transitions, 48–50
 bisulfite sequencing, 29–30
 BNM. *See* Brain Network Model
 Braess' paradox, 2–3
 brain, as complex adaptive system, 1–4
 Brain Network Model (BNM), 44–6
 brain networks. *See also* personalised network modelling
 near-decomposability of, 82–4
 neuroimaging investigations of, 127–8, 135–8, 149–50
 anti-seizure medications and, 146–7
 cognitive fMRI in, 146
 in FCD, 131–2
 future perspectives in, 132
 in GGE and IGE, 142–6
 graph-theoretical metrics of topology, 128
 imaging modalities for study of, 127–8, 135
 seed-based correlation in, 135–6
 spatial independent component analysis in, 136–7
 in TLE, 128–30, 136–7
 in TLE with secondary generalisation, 138–40
 TLR outcomes predictions from, 129, 140–1
 VNS outcomes predictions from, 147–9
 in xTLE, 141–2
 phenomenological models of, 42–5
 applications of, 53–7
 dynamical system theory and, 45–8
 in large-scale patient specific brain models, 45–6
 patient specific, 45–6, 61–3
 seizure evolution, 52–3
 seizure onset and offset, 47–52
 brain state hypothesis, 119
 brain tumours. *See* low-grade epilepsy-associated brain tumours
 CAE. *See* childhood absence epilepsy
 carbamazepine, 146–7
 Casual Reasoning Analytical Framework for Target discovery (CRAFT), 28
 catamenial epilepsy, 51
 cEI. *See* connectivity
 Epileptogenicity Index
 cell signaling, as multi-layer perceptron, 7–9
 cells, as complex adaptive systems, 1
 centrality, of nodes, 128
 childhood absence epilepsy (CAE), 142–6
 circadian rhythm, seizure clustering with, 51
 circuit view, of molecular networks, 7–9
 clustering coefficient, 128
 cognitive comorbidities of epilepsy, 86, 93–4
 cognitive fMRI in, 146
 cognitive performance, connectivity relationship to, 129, 131–2, 141–2
 coherence-based methods, for iEEG, 107–8

Index

- complex adaptive system, brain as, 1–4
- complex systems theory, 1–4, 72. *See also specific topics*
- complex traits, genetic architecture of, 6–9
- computational view, of molecular networks, 7–9
- concatenation-based data integration, 35
- connectivity, entropy relationship to, 79–83
- connectivity Epileptogenicity Index (cEI), 110–11
- connectivity matrix. *See* connectome
- connectivity-based spatial mapping methods
- iEEG, 101, 106–7, 115–16
- coherence-based methods, 107–8
- information theory, 111–12
- MVAR model and related measures, 108–9
- non-linear correlation coefficient, 110–11
- phase synchronization, 109–10
- scalp EEG, 101, 113–16
- connectome
- brain network models using, 43–5
- dynamical systems models with personalised, 61–3
- functional, 66–8
- structural, 63–5
- neuroimaging investigations of, 127–8, 135–7, 149–50
- anti-seizure medications and, 146–7
- cognitive fMRI in, 146
- in FCD, 131–2
- in GGE and IGE, 142–6
- in TLE, 128–9, 136–7
- in TLE with secondary generalisation, 138–40
- TLR outcomes predictions from, 129, 140–1
- VNS outcomes predictions from, 147–9
- in xTLE, 141–2
- patient specific models using, 45–6, 61–3
- in pre-ictal transition analysis, 119–20
- controllability, of brain networks, 128
- correlation dimension, 117–18
- cortical dysplasia. *See* focal cortical dysplasia
- cortical stimulation mapping (CSM), 74–7
- cortical tubers, 27–8
- count matrix, 26
- coupling filter, 88, 91
- CPA6 gene, 30–1
- CRAFT. *See* Casual Reasoning Analytical Framework for Target discovery
- Csf1R gene, 28
- CSM. *See* cortical stimulation mapping
- default mode network (DMN), 136–7
- DI. *See* directed information
- differential expression testing, 26
- diffusion tensor imaging (DTI), 127–8
- network research applications of, 135
- structural connectivity-based modelling from, 63–5
- VNS outcomes predictions from, 148–9
- directed information (DI), 111–12
- directed transfer function (DTF), 108–9, 113–15
- disease gene networks, 10
- DMN. *See* default mode network
- DNA-methylation, 19–20, 29
- epilepsy investigations and, 30–9
- profiling techniques for, 29–30
- DNMT1 and DNMT3A genes, 30–1
- droplet-based technologies, 23–4
- drug interventions
- complex systems theory understanding of, 3–4
- epilepsy genetic revolution and, 6
- fMRI-derived networks and, 146–7
- gene expression targets for, 12
- neuronal unit scale approaches to, 86, 93–4
- personalised network modelling and, 67–8
- response to, 28, 41–2, 61, 127, 146–7
- RNA-seq in identification of novel targets for, 28
- systems genetics in development of, 12–13
- transcriptome and epigenome analysis in development of, 19–20
- drug-resistant epilepsy, neuroimaging network-level approach to, 127–8
- FCD network mechanisms, 131–2
- future perspectives in, 132
- graph-theoretical metrics of topology, 128
- imaging modalities for study of, 127–8
- in TLE, 128–30
- DTF. *See* directed transfer function
- DTI. *See* diffusion tensor imaging
- dynamic functional connectivity in GGE and IGE, 142–6
- in TLE, 136–7
- dynamical systems models, 45–8
- EGG of epileptic network dynamics, 99, 116–17, 121–2
- machine learning algorithms, 118–21
- network theory approaches, 118–21
- pre-ictal state traces, 117–18
- personalised brain connectivity incorporation into, 61–3
- functional connectivity-based, 66–8
- opportunities and future of, 67–8
- structural connectivity-based, 63–5
- seizure classification and, 56–7
- seizure evolution and, 52–3
- seizure onset/offset and, 47–52
- in silico experiments and, 53–6, 64–70
- EC. *See* electrode connectivity
- ECoG. *See* electrocorticography
- ecosystems, interventions into, 3–4
- edges, of brain networks, 128
- EI. *See* Epileptogenicity Index
- electrical source imaging (ESI), 113–14
- electrocorticography (ECoG), 74–7, 99–101
- electrode connectivity (EC), 80–3
- electrode sample entropy (ESE), 80–3
- electroencephalography (EEG). *See also* invasive EEG; scalp EEG; simultaneous EEG-fMRI
- complex systems approach to, 72, 82–4
- applications of, 82–4
- pattern formation, 72–9
- statistical complexity, 79–83
- functional connectivity-based modelling from, 66–8
- network research applications of, 135
- seizure evolution patterns in, 52–3
- electrophysiological data, systems approaches to, 12–13
- emergent phenomena, of complex adaptive systems, 2
- ENCODE project, 19–20
- endophenotype, gene expression use as, 9–10
- ENIGMA-Epilepsy consortium, 132

- entropy. *See also* sample entropy
 in information theory, 111–12
- epigenome, 19–21
- epigenomic profiling, 19, 29, 35
 in epilepsy investigations, 30–9
 epitranscriptomics, 31
 machine learning application to,
 31–2
 data integration with, 33, 35
 in epilepsy research, 32–5
 methylation profiling techniques
 for, 29–30
- epilepsy. *See specific topics*
- epilepsy syndromes, terminology,
 135
- epileptiform discharges, 93
- epileptogenic network, 99–101
- epileptogenic zone (EZ)
 EEG localization of, 99–101,
 121–2
 connectivity-based methods for
 iEEG, 101, 106–12, 115–16
 single-node epileptogenicity
 biomarkers, 101–5, 115–16
 source inversion and network-
 based applications for scalp
 EEG, 101, 113–16
- phenomenological models of,
 41–2, 63–4
 Virtual Epileptic Patient, 45–6
 virtual surgeries and
 stimulations using, 53–5
- Epileptogenicity Index (EI), 102–3,
 110–11
- Epileptor model, 50–3, 55–6, 63–4
- epistasis, 9–12
- epitranscriptomics, 31
- ESE. *See* electrode sample entropy
- Esf1* locus, 11
- ESI. *See* electrical source imaging
- event filter,
 90–1
- Everolimus, 16
- excitability
 in large-scale patient specific
 brain models, 45–6
 in seizure onset/offset, 47–8, 52
- excitable models, of noise-induced
 transitions, 50
- excitatory-inhibitory balance, at
 neuronal level, 93
- expression matrix, 26
- extra temporal lobe epilepsy (xTLE),
 141–2
- EZ. *See* epileptogenic zone
- fast variables, in phenomenological
 models of seizure activity,
 48, 50–3
- FBTCS. *See* focal to bilateral tonic
 clonic seizures
- FCD. *See* focal cortical dysplasia
- FISH. *See* fluorescence in situ
 hybridisation
- FitzHugh-Nagumo model,
 55–6
- fixed points, in dynamical system
 models of seizure, 45–50
- FLE. *See* frontal lobe epilepsy
- fluorescence in situ hybridisation
 (FISH), spatial
 transcriptomic information
 from, 24–5
- fMRI. *See* functional magnetic
 resonance imaging
- focal cortical dysplasia (FCD),
 127–8
 DNA methylation analysis in,
 30–1
 fMRI of network alterations in,
 141–2
 neuroimaging of network
 alterations in, 131–2
- focal epilepsies. *See also specific focal
 epilepsies*
 network models of, 41–2, 45–6,
 149–50
 personalised network modelling
 of, 63–4, 66
 simultaneous EEG-fMRI of,
 135–8
- focal to bilateral tonic clonic
 seizures (FBTCS), 138–40
- frequencies of interest (FOIs), 103–5
- frequency-specific biomarkers, of
 epileptogenicity, 102–4
- frontal lobe epilepsy (FLE),
 141–2
- functional connectivity. *See also*
 functional magnetic
 resonance imaging
 neuroimaging investigations of,
 127–8
 in FCD, 131–2
 in TLE, 128–9, 136–7
 personalised patient-derived
 networks from, 66–8
 in pre-ictal transition analysis,
 119–20
- functional gene networks, 10
- functional magnetic resonance
 imaging (fMRI)
 in history of epilepsy research,
 135
 network alterations in epilepsy
 from, 135–8, 149–50
 anti-seizure medications and,
 146–7
 cognitive fMRI in, 146
 in FCD, 131–2
 in GGE and IGE, 142–6
 in TLE, 128–9, 136–7
 in TLE with secondary
 generalisation, 138–40
- TLR outcomes predictions
 from, 129, 140–1
- VNS outcomes predictions
 from, 147–9
 in xTLE, 141–2
- network research applications of,
 127–8, 135
- rs-fMRI investigations of brain
 networks, 135
 seed-based correlation, 135–6
 spatial independent component
 analysis, 136–7
- Gabra2* gene, 11
- GDR. *See* genome-based drug
 repurposing
- gene count matrix, 26
- gene expression, 19–20. *See also*
 epigenome; transcriptome
- gene expression networks, 9–10, 12
- gene mutations. *See also* single gene
 mutations
 complexity of epilepsy-associated,
 5–6
 drug targets from, 12
 model system studies of, 10–12
 network interactions and
 perturbations of, 7–9
 number of possible, 6
 phenotype prediction from, 6–9
 polygenic modelling of, 12–13
- generalised epilepsies, personalised
 network modelling of, 64–70
- generalised genetic epilepsy (GGE),
 142–6
- generalised spike wave (GSW),
 142–6
 personalised network modelling
 of, 64–70
- generalized linear model (GLM),
 neuronal firing modelling
 using, 88–91
- generalized tonic-clonic seizure
 (GTCS), 142–6
- genetic analysis
 complex trait architecture and,
 6–9
 high-throughput molecular
 techniques, 5–6
 network-based approaches,
 5, 7–9
 functional gene networks, 10
 future outlook of, 12–13
 gene expression networks,
 9–10, 12
 model system studies of risk
 factors and modifiers,
 10–12
- genetic epilepsies, 2. *See also specific
 genetic epilepsies*
- genome, 19–20. *See also* epigenome;
 transcriptome

Index

- genome-based drug repurposing (GDR), 12
- genome-wide association studies (GWAS), 5–6
- genetic architecture of traits and, 6–9
- network-based technique use with, 9–10
- novel phenotyping approaches in, 12–13
- genome-wide DNA methylation analysis, 29–31
- genotype-phenotype maps, 6–10
- GGE. *See* generalised genetic epilepsy
- GLM. *See* generalized linear model
- graph theory, 128
- neuroimaging analyses utilising in FCD, 131–2
- in TLE, 128–30
- GSW. *See* generalised spike wave
- GTCS. *See* generalized tonic-clonic seizure
- GWAS. *See* genome-wide association studies
- height, genetics of, 7
- HFOs. *See* high frequency oscillations
- HGP. *See* Human Genome Project
- high frequency oscillations (HFOs), 93, 103
- high-throughput molecular techniques, 5–6. *See also* next-generation sequencing
- hippocampal sclerosis, 30–1
- hippocampus, 94
- in TLE, 136–7
- hubs, of brain networks, 128
- Human Genome Project (HGP), 19–20
- hypertension, NetWAS study of, 10
- ICA. *See* independent component analysis
- ICNs. *See* intrinsic connectivity networks
- ictal core, 91–2
- ictal onset pattern (IOP), 103
- ictal state, interictal state transition to, 47–52
- idiopathic generalized epilepsy (IGE)
- fMRI of network alterations in, 142–6
- GWAS of, 5–6
- iEEG. *See* invasive EEG
- IGE. *See* idiopathic generalized epilepsy
- ILAE. *See* International League Against Epilepsy
- imaging genetics, 12–13
- in silico experiments, 53–6, 64–70
- independent component analysis (ICA), spatial, 136–7
- Infinium 450k and 850k microarrays, 29–30
- information flow, of complex adaptive systems, 1
- information theory, for iEEG, 111–12
- inhibition, interneuron loss of, 91–3
- interaction view, of molecular networks, 7–9
- interictal spikes
- neuronal unit scale approaches to, 93
- phenomenological models of, 53
- interictal state, ictal state transition to, 47–52
- intermediate variables, in
- phenomenological models of seizure activity, 52–3
- intermittency, in seizure onset/offset, 47–8
- internal models, complex adaptive system use of, 1
- International League Against Epilepsy (ILAE), GWAS mega-analysis published by, 5–6
- interneurons, inhibition loss by, 91–3
- intrinsic connectivity networks (ICNs), fMRI investigations of, 136–7, 149–50
- anti-seizure medications and, 146–7
- cognitive fMRI in, 146
- in GGE and IGE, 142–6
- in TLE, 128–9, 136–7
- in TLE with secondary generalisation, 138–40
- TLR outcomes predictions from, 129, 140–1
- VNS outcomes predictions from, 147–9
- in xTLE, 141–2
- invasive EEG (iEEG)
- epileptic network dynamics for seizure prediction using, 99, 116–17, 121–2
- machine learning algorithms, 118–21
- network theory approaches, 118–21
- pre-ictal state traces, 117–18
- functional connectivity-based modelling from, 66–8
- pattern formation of, 72–9
- spatial mapping of epileptic networks with, 99–101, 121–2
- connectivity-based methods for, 101, 106–12, 115–16
- single-node epileptogenicity biomarkers, 101–5, 115–16
- statistical complexity of, 79–83
- IOP. *See* ictal onset pattern
- Iso-Seq, 25
- JAE. *See* juvenile absence epilepsy
- JME. *See* juvenile myoclonic epilepsy
- juvenile absence epilepsy (JAE), 142–6
- juvenile myoclonic epilepsy (JME), 142–6
- KCNJ10 gene, 11
- ketamine, 146–7
- Kolmogorov-Sinai (KS) entropy, 79–82
- Kuramoto model, 72–4
- of ADs, 75–8, 82–4
- lamotrigine, 146–7
- language areas, fMRI identification of, 146
- lateralized periodic discharges (LPDs), 77–9
- LEATs. *See* low-grade epilepsy-associated brain tumours
- levetiracetam, 146–7
- LFP. *See* local field potential
- limit cycles, in dynamical system models of seizure, 45–50
- link function, 90
- links, of brain networks, 42–5
- local field potential (LFP), 87–8, 91–4
- longitudinal studies, personalised network modelling in, 67–8
- low-grade epilepsy-associated brain tumours (LEATs), 30–1
- LPDs. *See* lateralized periodic discharges
- Lyapunov exponent, 117–18
- machine learning (ML), 31–2
- data integration with, 33, 35
- in epilepsy research, 32
- feature selection issues in, 34–5
- missing data issues, 32–4
- sample size issues, 32, 34
- seizure prediction with, 118–21
- magnetic resonance imaging (MRI). *See also* functional magnetic resonance imaging
- of drug-resistant epilepsy, 127–8
- in FCD, 131–2
- in TLE, 128–30
- network research applications of, 135

- structural connectivity-based modelling from, 63–5
- magnetoencephalography (MEG) network research applications of, 135
- VNS outcomes predictions from, 148–9
- memory, 94
- mesial temporal lobe epilepsy (MTLE), 102–3
- mesoscopic scale of seizure activity, 41–4. *See also* phenomenological models of seizure
- MI. *See* mutual information
- microRNAs (miRNAs), 22–3 in TSC, 27–8
- ML. *See* machine learning
- model inversion, in personalised network modelling, 67
- model system studies, of risk and modifier genes, 10–12
- model-based data integration, 35
- modifier genes, model system studies of, 10–12
- modules, of brain networks, 128
- molecular networks, 7–9
- monogenic epilepsies complex systems theory understanding of, 2 genetic analysis of, 5–6 network-level effects in, 7
- motifs, network, 7–9
- mouse models, of risk and modifier genes, 10–12
- MRI. *See* magnetic resonance imaging
- MTLE. *See* mesial temporal lobe epilepsy
- mTOR pathway mutations, 6
- multi-layer perceptron, cell signaling as, 7–9
- multimodal data integration, in personalised network modelling, 67
- multi-omic studies, 12–13, 33, 35
- multi-spectral biomarkers, of epileptogenicity, 103–5
- multi-unit recordings, 88–94
- multivariate autoregressive (MVAR) model, for iEEG, 108–9
- mutual information (MI), 111–12
- MVAR model. *See* multivariate autoregressive model
- nanopore based sequencer, 25
- near-decomposability, of brain networks, 82–4
- NetWAS. *See* Network-wide Association Study
- networks. *See also* brain networks; *specific topics*
- disease gene, 10
- gene expression, 9–10, 12
- interventions into, 2–3
- terminology, 135
- transcriptional, 7–9
- Network-wide Association Study (NetWAS), 10
- Neural Field Models (NFM), 44–5
- Neural Mass Model (NMM), 42–5 applications of, 53–7 in large-scale patient specific brain models, 45–6 of seizure activity, 45 dynamical system theory and, 45–8 seizure evolution, 52–3 seizure onset and offset mechanisms, 47–52
- neural networks, 42–5 as complex adaptive systems, 1 single and multi-unit recordings of, 88–94 topological properties of, 2
- neural population models, 61–3
- neuroimaging. *See also specific imaging modalities* techniques used in network investigations, 127–8, 135
- neuronal activity, epilepsy approaches utilising, 86–7, 89, 94
- GLM modelling, 88–91
- multi-unit recordings, 88–94
- point process modelling, 89
- single unit recordings, 88–94
- unit level mechanisms underlying cognitive dysfunction, 93–4
- unit level mechanisms underlying epilepsy, 93
- unit level mechanisms underlying seizures, 91–3
- neurons as agents in complex adaptive system, 1 as nodes of neural networks, 42–5 synchronizability of, 2
- neurostimulator implantation, 2–3. *See also* stimulation
- next-generation sequencing, 20 current technologies in RNA-seq, 20–2 single-cell and single-nuclei RNA-seq, 23–4 small RNA-seq, 22–3 spatial transcriptomics, 24–5
- data analysis techniques for, 25–6 differential expression testing, 26 other techniques, 27
- read alignment and quantification of expression, 26
- epilepsy research utilising, 27–35 biomarker detection with small RNA-seq, 29 drug target identification with RNA-seq, 28 transcription factor identification with RNA-seq, 28–9 TSC investigations with small RNA-seq and RNA-seq, 27–8
- machine learning application to, 31–2 data integration with, 33, 35 in epilepsy research, 32–5
- NFMs. *See* Neural Field Models
- NMM. *See* Neural Mass Model
- nodes, of brain networks, 42–5, 128
- noise-induced transition, in seizure onset/offset, 47–51
- non-linear correlation coefficient, for iEEG, 110–11
- non-linear dynamic measures, 117–18
- nonlinear interactions, of complex adaptive systems, 1
- omnigenic inheritance, 6–7
- onset/offset seizure mechanisms dynamical systems models of, 61–3 excitability, 47–8, 52 mixed scenario with slow dynamics, 51 at neuronal scale, 91–2 noise-induced transitions, 47–51 patient specific bifurcations, 51–2 slow-variable dynamics and bifurcations, 50–1 status epilepticus and, 52
- path length, 128
- patient-specific network models. *See also* personalised network modelling applications of, 53–6 large-scale brain, 45–6, 61–3
- patient-specific onset/offset mechanisms, 51–2
- penumbra, seizure, 91–2
- peri-event time histograms (PETH), 89–91
- periodic lateralized epileptiform discharges (PLEDs), 77–9
- permittivity variable, in phenomenological models of seizure activity, 50–1
- personalised network modelling, 61–8

Index

- personalised network modelling (cont.)
 dynamical systems models with personalised brain connectivity, 61–3
 functional connectivity-based, 66–8
 opportunities and future of, 67
 long-term longitudinal properties, 67–8
 multimodal data integration, 67
 within-subject variability, 68
 structural connectivity-based, 63–5
- PETH. *See* peri-event time histograms
- phase synchronization, for iEEG, 109–10
- phenomenological models of seizure, 41–58
 applications and future directions of, 63–4
 dynamics as classification criterion, 56–7
 in silico experiments, 53–6, 64–70
 background, 41–2
 large-scale patient specific brain models, 45–6, 61–3
 network approaches to brain models, 42–5
 NMMs of seizure activity, 45
 dynamical system theory and, 45–8
 seizure evolution, 52–3
 seizure onset and offset mechanisms, 47–52
- phenotype
 GWAS in prediction of, 6–9
 novel approaches to, 12–13
 systems genetic analysis in prediction of, 9–10
- PLEDs. *See* periodic lateralized epileptiform discharges
- PLX3397, 28
- point mutations, genetic architecture of traits and, 6–9
- point processes, neuronal firing modelling as, 89
- polygenic epilepsies
 genetic analysis of, 5–6
 network-based approaches to, 7–9
- polygenic risk modelling, 12–13
- polygenic traits, 6–9
- population dynamics, of neuronal action potential firing, 88
- post-spike filter, 88, 91
- precision medicine, epilepsy genetic revolution and, 6
- preictal spikes, 53
- pre-ictal state
 EEG dynamical traces of, 117–18
 mechanistic interpretations, 118
 non-linear dynamic measures, 117–18
 network theory approaches to, 118–21
- propagation, at neuronal scale, 91–2
- propagation zone (PZ),
 phenomenological models of, 41–2
 Virtual Epileptic Patient, 45–6
 virtual surgeries and stimulations using, 53–5
- protein-protein interaction networks, 7–9
- psychiatric comorbidities of epilepsy, 86, 94
- PZ. *See* propagation zone
- rate dynamics, of neuronal action potential firing, 88
- read alignment, 26
- RELN* gene, 30–1
- resection. *See* surgical resection
- resting state fMRI (rs-fMRI), brain network investigations utilising, 127–8, 135
- seed-based correlation, 135–6
- spatial independent component analysis, 136–7
- rich-club phenomenon, 128
- risk genes, 10–13
- risperidone, 146–7
- RNA expression. *See* transcriptome
- RNA modifications, 31
- RNA-sequencing (RNA-seq), 20–2
 data analysis techniques for, 25–6
 differential expression testing, 26
 other techniques, 27
 read alignment and quantification of expression, 26
 epilepsy research utilising, 27–35
 biomarker detection, 29
 drug target identification, 28
 transcription factor identification, 28–9
 TSC investigations, 27–8
 single-cell and single-nuclei, 23–4
 small, 22–3, 27–35
 spatial information and, 24–5
 third-generation, 25
- rs-fMRI. *See* resting state fMRI
- sample entropy (SE), 79–83
- scalp EEG
 epileptic network dynamics for seizure prediction using, 99, 116–17, 121–2
 machine learning algorithms, 118–21
 network theory approaches, 118–21
 pre-ictal state traces, 117–18
 functional connectivity-based modelling from, 66–8
 pattern formation, 72–9
 spatial mapping of epileptic networks with, 101, 113–16
- schizophrenia, 10
- scRNA-seq. *See* single-cell RNA-seq
- SE. *See* sample entropy
- secondary generalisation, TLE with, 138–40
- second-generation sequencing. *See* next-generation sequencing
- seed-based correlation, 135–6
- SEEG. *See* stereoelectroencephalography
- seizure
 dynamical systems models of, 61–3
 EEG prediction of, 99, 116–17, 121–2
 machine learning algorithms, 118–21
 network theory approaches, 118–21
 pre-ictal state traces, 117–18
 long-term longitudinal properties of, 67–8
 phenomenological models of, 41–58, 63–4
 classification using, 56–7
 dynamical system theory and, 45–8
 large-scale patient specific brain models, 45–6, 61–3
 network-based brain models, 42–5
 seizure evolution, 52–3
 seizure onset and offset mechanisms, 47–52
 in silico experiments using, 53–6, 64–70
 unit level mechanisms underlying, 91–3
 within-subject variability of, 68
- seizure onset zone (SOZ), 99–101
 iEEG localization of, 101–5
 scalp EEG localization of, 101, 113–16
- self-organised criticality, at neuronal level, 93
- sensorimotor network, in GGE and IGE, 142–6
- sequential-FISH+ (seqFISH+), 24–5
- SESN3, 9–10

- side effects, drug, personalised
network modelling of,
67–8
- signaling cascade, as multi-layer
perceptron, 7–9
- simultaneous EEG-fMRI
in history of epilepsy research,
135
network alterations in epilepsy
from, 135–8, 149–50
anti-seizure medications and,
146–7
cognitive fMRI in, 146
in GGE and IGE, 142–6
in TLE, 136–7
in TLE with secondary
generalisation, 138–40
TLR outcomes predictions
from, 140–1
VNS outcomes predictions
from, 147–9
in xTLE, 141–2
- single gene mutations
complex systems theory
understanding of, 2
genetic analysis of, 5–6
- single nucleotide polymorphisms
(SNPs), genetic architecture
of traits and, 6–9
- single unit dynamics
recordings of, 88–94
of seizure, 91–3
- single-cell RNA-seq (scRNA-seq),
23–4
- single-molecule real time (SMRT)
sequencer, 25
- single-node epileptogenicity
biomarkers, 101–2, 115–16
frequency-specific, 102–4
multi-spectral, 103–5
- single-nuclei RNA-seq (snRNA-
seq), 23–4
- sitagliptin, 12
- Slide-seq, 24–5
- slow variables, in phenomenological
models of seizure activity,
48, 50–3
- small RNA-seq, 22–3, 27–35
biomarker detection with, 29
TSC investigations utilising, 27–8
- small-world networks, 2
- SMRT sequencer. *See*
single-molecule real time
sequencer
- SNIC bifurcations, 50
- SNPs. *See* single nucleotide
polymorphisms
- snRNA-seq. *See* single-nuclei
RNA-seq
- sodium channel mutations, 2
- sodium valproate, 146–7
- source inversion, EEG, 101, 113–16
- SOZ. *See* seizure onset zone
- spatial cognition, 94
- spatial independent component
analysis, 136–7
- spatial mapping of epileptic
networks, 99–101, 121–2
connectivity-based methods for,
101, 106–7, 115–16
coherence-based methods,
107–8
information theory,
111–12
MVAR model and related
measures, 108–9
non-linear correlation
coefficient, 110–11
phase synchronization, 109–10
- single-node epileptogenicity
biomarkers, 101–2, 115–16
frequency-specific, 102–4
multi-spectral, 103–5
- source inversion and network-
based applications for scalp
EEG, 101, 113–16
- spatial transcriptomics, 24–5
- spike train, 89
- spike-and-wave discharges (SWDs),
64–70
- spikes, 89. *See also* action potentials
phenomenological models of,
52–3
- state space, in dynamical system
theory, 45–7
- state variables, in dynamical system
theory, 45–7
- statistical epistasis, 9
- statistical genetics, network-based
technique augmentation of,
10
- status epilepticus, 52, 92–3
- stereoelectroencephalography
(SEEG), 99–101
- stimulation
fMRI-derived networks in
outcomes predictions for,
147–9
neuronal unit scale approaches to,
86, 94
phenomenological model use in,
41–2
in silico experiments, 53–5
- structural connectivity
neuroimaging investigations of,
127–8
in FCD, 131–2
in TLE, 128–30, 136–7
VNS outcomes predictions
from, 148–9
personalised patient-derived
networks from, 63–5
- supervised machine learning, 31–2
- surgical resection
complex systems theory
understanding of, 2–3
long-term outcomes of, 67–8
neuronal unit scale approaches to,
86, 91–2, 94
personalised network modelling
use in, 63–70
phenomenological model use in,
41–2, 53–5, 63–70
temporal lobe, 129, 140–1
- SWDs. *See* spike-and-wave
discharges
- synaptic connections, as links of
neural networks, 42–5
- synchronisation, personalised
network modelling of, 64–70
- synchronizability, of networks, 2
- systems biology, 9–10
- systems genetics, 5, 9
drug targets from, 12
functional gene networks, 10
future outlook of, 12–13
gene expression networks, 9–10,
12
model system studies of risk
factors and modifiers, 10–12
- Szsl locus, 11
- tagging, complex adaptive system
use of, 1
- TBI. *See* traumatic brain injury
- TE. *See* transfer entropy
- temporal lobe epilepsy (TLE), 127–8
cognitive fMRI in, 146
DNA methylation analysis in,
30–1
epileptogenic zone mapping of,
102–3
GDR application to, 12
GWAS of, 5–6
neuroimaging of network
alterations in, 136–7
altered network mechanisms,
128–30
secondary generalisation,
138–40
TLR outcomes predictions
from, 129, 140–1
xTLE, 141–2
personalised network modelling
of, 63–4
RNA-seq in identification of
novel drug targets in, 28
systems genetic analysis of, 9–10
temporal lobe resection (TLR), 129,
140–1
- thalamus
in secondary generalised seizures,
138–40
VNS therapeutic effects and,
147–9
- theta phase precession, 90

Index

- theta-phase preference, 90
 third-generation sequencing, 25
 timing dynamics, of neuronal action potential firing, 88
 TLE. *See* temporal lobe epilepsy
 TLR. *See* temporal lobe resection
 topology, network, 2
 graph theoretical analysis of, 128
 in FCD, 131–2
 in TLE, 128–30
 tractography, 63–5, 127–8
 traffic networks, interventions into, 2–3
 traits, genetic architecture of, 6–9
 transcript count matrix, 26
 transcription factors, RNA-seq in
 identification of, 28–9
 transcriptional networks, 7–9
 transcriptome, 19–21
 transcriptome profiling, 19–20, 35
 current technologies in
 RNA-seq, 20–2
 single-cell and single-nuclei
 RNA-seq, 23–4
 small RNA-seq, 22–3
 spatial transcriptomics, 24–5
 third-generation sequencing, 25
 data analysis techniques for,
 25–6
 differential expression testing,
 26
 other techniques, 27
 read alignment and
 quantification of expression,
 26
 epilepsy research utilising, 27–35
 biomarker detection with small
 RNA-seq, 29
 drug target identification with
 RNA-seq, 28
 transcription factor
 identification with RNA-seq,
 28–9
 TSC investigations with small
 RNA-seq and RNA-seq,
 27–8
 epitranscriptomics, 31
 machine learning application to,
 31–2
 data integration with, 33, 35
 in epilepsy research, 32–5
 transfer entropy (TE), 111–12
 traumatic brain injury (TBI)
 outcomes variability following, 2
 RNA-seq investigations of, 28–9
 tuberous sclerosis complex (TSC), 2,
 7, 27–8
 unit scale, epilepsy approaches at,
 86–7, 89, 94
 cognitive dysfunction
 mechanisms, 93–4
 epilepsy mechanisms, 93
 multi-unit recordings, 88–94
 neuronal firing modelling as point
 processes, 89
 neuronal firing modelling using
 GLM approach, 88–91
 seizure mechanisms,
 91–3
 single unit recordings, 88–94
 unsupervised machine learning,
 31–2
 vagus nerve stimulation (VNS),
 147–9
 Virtual Epileptic Patient (VEP)
 model, 45–6
 virtual surgeries and stimulations,
 53–5
 VNS. *See* vagus nerve stimulation
 waves, EEG, 52–3
 whole genome bisulfite sequencing
 (WGBS), 29–30
 whole-exome sequencing, 5–6
 whole-genome sequencing,
 5–6
 Wilson-Cowan model, 43–4
 within-subject variability, in
 personalised network
 modelling, 68
 working memory, 94
 xTLE. *See* extra temporal lobe
 epilepsy